Suppr超能文献

相似文献

1
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.
EMBO Rep. 2016 Feb;17(2):188-201. doi: 10.15252/embr.201540488. Epub 2015 Dec 21.
2
Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.
Oncogene. 2017 Jun 22;36(25):3515-3527. doi: 10.1038/onc.2016.518. Epub 2017 Feb 6.
4
6
Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner.
Nat Commun. 2018 Jun 12;9(1):2301. doi: 10.1038/s41467-018-04757-w.
8
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP.
Genes Dev. 2010 Nov 1;24(21):2430-9. doi: 10.1101/gad.1954310.
9
Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP.
Sci Signal. 2016 Mar 1;9(417):ra23. doi: 10.1126/scisignal.aaa9227.
10
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
J Cell Mol Med. 2020 Jan;24(1):1087-1098. doi: 10.1111/jcmm.14841. Epub 2019 Nov 21.

引用本文的文献

2
Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.
ACS Nano. 2025 Apr 15;19(14):13685-13704. doi: 10.1021/acsnano.4c14625. Epub 2025 Apr 2.
3
Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73.
Acta Pharmacol Sin. 2025 Jun;46(6):1722-1732. doi: 10.1038/s41401-025-01474-1. Epub 2025 Feb 10.
4
The Hippo Signaling Pathway Manipulates Cellular Senescence.
Cells. 2024 Dec 26;14(1):13. doi: 10.3390/cells14010013.
7
Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.
J Mol Med (Berl). 2024 Dec;102(12):1485-1501. doi: 10.1007/s00109-024-02499-5. Epub 2024 Oct 31.
8
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).
Int J Mol Med. 2025 Jan;55(1). doi: 10.3892/ijmm.2024.5448. Epub 2024 Oct 25.
9
Blockade of Crk eliminates Yki/YAP-activated tumors via JNK-mediated apoptosis in Drosophila.
Commun Biol. 2024 Sep 28;7(1):1196. doi: 10.1038/s42003-024-06897-w.
10
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects.
Biomedicines. 2024 Sep 2;12(9):1979. doi: 10.3390/biomedicines12091979.

本文引用的文献

1
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.
Oncotarget. 2015 Aug 7;6(22):19087-101. doi: 10.18632/oncotarget.4236.
3
Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.
Mol Cell. 2014 Dec 4;56(5):617-29. doi: 10.1016/j.molcel.2014.10.013. Epub 2014 Nov 13.
4
The biology of YAP/TAZ: hippo signaling and beyond.
Physiol Rev. 2014 Oct;94(4):1287-312. doi: 10.1152/physrev.00005.2014.
5
Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration.
Mitochondrion. 2014 Nov;19 Pt A:88-96. doi: 10.1016/j.mito.2014.08.003. Epub 2014 Aug 15.
6
TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Clin Cancer Res. 2014 Jul 1;20(13):3569-80. doi: 10.1158/1078-0432.CCR-13-2943. Epub 2014 May 6.
7
The cytoplasmic side of p53's oncosuppressive activities.
FEBS Lett. 2014 Aug 19;588(16):2600-9. doi: 10.1016/j.febslet.2014.04.015. Epub 2014 Apr 18.
8
The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.
Development. 2014 Apr;141(8):1614-26. doi: 10.1242/dev.102376.
9
Metabolic control of YAP and TAZ by the mevalonate pathway.
Nat Cell Biol. 2014 Apr;16(4):357-66. doi: 10.1038/ncb2936. Epub 2014 Mar 23.
10
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98. doi: 10.1073/pnas.1319190110. Epub 2013 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验